Q4 2022 Earnings Forecast for Pfizer Inc. Issued By SVB Leerink (NYSE:PFE)

Pfizer Inc. (NYSE:PFEGet Rating) – Research analysts at SVB Leerink lowered their Q4 2022 EPS estimates for Pfizer in a report released on Friday, July 29th. SVB Leerink analyst D. Risinger now expects that the biopharmaceutical company will earn $1.35 per share for the quarter, down from their prior forecast of $1.48. SVB Leerink has a “Market Perform” rating and a $53.00 price target on the stock. The consensus estimate for Pfizer’s current full-year earnings is $6.67 per share. SVB Leerink also issued estimates for Pfizer’s Q2 2023 earnings at $1.39 EPS, Q4 2023 earnings at $1.34 EPS, FY2023 earnings at $5.63 EPS and FY2026 earnings at $4.29 EPS.

Several other equities research analysts also recently weighed in on PFE. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research note on Tuesday, June 28th. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. The Goldman Sachs Group set a $50.00 price target on shares of Pfizer in a report on Friday. Wells Fargo & Company cut their price target on shares of Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. Finally, Barclays set a $52.00 price target on shares of Pfizer in a report on Thursday, July 7th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Pfizer Trading Down 0.4 %

Shares of PFE opened at $50.51 on Monday. Pfizer has a twelve month low of $40.94 and a twelve month high of $61.71. The company has a market cap of $283.41 billion, a P/E ratio of 11.58, a P/E/G ratio of 0.62 and a beta of 0.73. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. The company’s fifty day simple moving average is $51.46 and its 200-day simple moving average is $51.22.

Pfizer (NYSE:PFEGet Rating) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The company had revenue of $27.74 billion for the quarter, compared to the consensus estimate of $26.20 billion. During the same quarter in the prior year, the firm earned $1.07 earnings per share. Pfizer’s revenue was up 46.8% on a year-over-year basis.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently made changes to their positions in the company. Norges Bank acquired a new stake in Pfizer in the 4th quarter valued at $3,351,891,000. Capital International Investors raised its holdings in shares of Pfizer by 3,059.6% during the 1st quarter. Capital International Investors now owns 38,530,003 shares of the biopharmaceutical company’s stock worth $1,994,698,000 after acquiring an additional 37,310,556 shares during the period. Vanguard Group Inc. raised its holdings in Pfizer by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 479,065,273 shares of the biopharmaceutical company’s stock valued at $24,801,210,000 after buying an additional 13,790,348 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Pfizer by 577.8% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,247,903 shares of the biopharmaceutical company’s stock valued at $715,270,000 after buying an additional 10,440,786 shares during the period. Finally, Coatue Management LLC purchased a new stake in Pfizer during the fourth quarter worth about $608,919,000. Institutional investors and hedge funds own 66.50% of the company’s stock.

Insider Activity

In related news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the transaction, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the completion of the transaction, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at approximately $585,250.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the transaction, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at $1,907,300. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,126 shares of company stock worth $2,075,003. Corporate insiders own 0.05% of the company’s stock.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.17%. The ex-dividend date of this dividend is Thursday, July 28th. Pfizer’s dividend payout ratio is currently 36.70%.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Earnings History and Estimates for Pfizer (NYSE:PFE)

Want More Great Investing Ideas?

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.